Literature DB >> 10076924

Effect of an angiotensin II receptor antagonist, candesartan, on insulin resistance and pressor mechanisms in essential hypertension.

K Higashiura1, N Ura, Y Miyazaki, K Shimamoto.   

Abstract

Candesartan (8 mg/d) was administered for 2 weeks to eight patients with essential hypertension to investigate the effect of an angiotensin II receptor antagonist on insulin sensitivity. The effect of candesartan on sodium-retaining action and the activation of pressor systems by hyperinsulinaemia, which might be related to pressor mechanisms in essential hypertension, was also investigated in this study. In patients with essential hypertension, candesartan restored insulin sensitivity to the level of that in normotensive subjects. Candesartan treatment attenuated the sodium-retaining action of hyperinsulinaemia. These findings suggest that inhibition of angiotensin II action by candesartan can improve insulin sensitivity and inhibit the sodium-retaining action associated with hyperinsulinaemia in essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10076924     DOI: 10.1038/sj.jhh.1000748

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  9 in total

Review 1.  The metabolic syndrome and related cardiovascular risk.

Authors:  F Ramos; H P Baglivo; A J Ramírez; R Sánchez
Journal:  Curr Hypertens Rep       Date:  2001-04       Impact factor: 5.369

2.  Angiotensin II receptor blocker-induces blunted taste sensitivity: comparison of candesartan and valsartan.

Authors:  Shuichi Tsuruoka; Michi Wakaumi; Takashi Ioka; Hisashi Yamamoto; Hitoshi Ando; Kohichi Sugimoto; Akio Fujimura
Journal:  Br J Clin Pharmacol       Date:  2005-08       Impact factor: 4.335

Review 3.  Inflammation and the metabolic syndrome: role of angiotensin II and oxidative stress.

Authors:  León Ferder; Felipe Inserra; Manuel Martínez-Maldonado
Journal:  Curr Hypertens Rep       Date:  2006-06       Impact factor: 5.369

Review 4.  Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.

Authors:  André J Scheen
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 5.  Angiotensin and insulin resistance: conspiracy theory.

Authors:  Raymond R Townsend
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

Review 6.  The choice of antihypertensive drugs in patients with diabetes: angiotensin II and beyond.

Authors:  Kambiz Kalantarinia; Helmy M Siragy
Journal:  Curr Diab Rep       Date:  2002-10       Impact factor: 4.810

Review 7.  The role of the angiotensin system in cardiac glucose homeostasis: therapeutic implications.

Authors:  Elena Bernobich; Luisa de Angelis; Carlos Lerin; Giuseppe Bellini
Journal:  Drugs       Date:  2002       Impact factor: 9.546

8.  Beneficial effect of combination therapy with antihypertensive drugs in patients with hypertension.

Authors:  Chihiro Shikata; Tetsuaki Sekikawa; Nobuaki Kimura; Akira Kojima; Shingo Seki; Hisayoshi Oka; Akihiro Nishiyama; Nobuakira Takeda
Journal:  Exp Clin Cardiol       Date:  2007

9.  Candesartan cilexetil improves angiotensin II type 2 receptor-mediated neurite outgrowth via the PI3K-Akt pathway in fructose-induced insulin-resistant rats.

Authors:  Narumi Hashikawa-Hobara; Naoya Hashikawa; Yusuke Inoue; Hitomi Sanda; Yoshito Zamami; Shingo Takatori; Hiromu Kawasaki
Journal:  Diabetes       Date:  2012-02-22       Impact factor: 9.461

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.